Estabrook Capital Management Trims Position in Humana Inc. (NYSE:HUM)

Estabrook Capital Management lowered its holdings in Humana Inc. (NYSE:HUM) by 8.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 596 shares of the insurance provider’s stock after selling 55 shares during the quarter. Estabrook Capital Management’s holdings in Humana were worth $223,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Intech Investment Management LLC raised its stake in shares of Humana by 46.2% during the 4th quarter. Intech Investment Management LLC now owns 42,287 shares of the insurance provider’s stock valued at $19,359,000 after buying an additional 13,356 shares during the last quarter. AdvisorShares Investments LLC acquired a new position in Humana in the fourth quarter valued at approximately $421,000. Sei Investments Co. lifted its holdings in Humana by 0.4% in the first quarter. Sei Investments Co. now owns 61,897 shares of the insurance provider’s stock valued at $21,462,000 after acquiring an additional 264 shares during the period. Cetera Advisors LLC boosted its position in Humana by 472.1% in the 1st quarter. Cetera Advisors LLC now owns 10,098 shares of the insurance provider’s stock worth $3,501,000 after purchasing an additional 8,333 shares in the last quarter. Finally, Cetera Investment Advisers grew its stake in shares of Humana by 249.0% during the 1st quarter. Cetera Investment Advisers now owns 20,945 shares of the insurance provider’s stock worth $7,262,000 after purchasing an additional 14,944 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Price Performance

HUM stock opened at $310.41 on Friday. Humana Inc. has a 1 year low of $298.61 and a 1 year high of $530.54. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.66 and a quick ratio of 1.66. The firm has a market capitalization of $37.40 billion, a PE ratio of 19.33, a price-to-earnings-growth ratio of 2.56 and a beta of 0.50. The business has a 50 day simple moving average of $357.71 and a 200-day simple moving average of $345.61.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, topping analysts’ consensus estimates of $5.89 by $1.07. Humana had a return on equity of 16.12% and a net margin of 1.53%. The company had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same quarter in the previous year, the company posted $8.94 earnings per share. The firm’s revenue for the quarter was up 10.4% compared to the same quarter last year. Equities research analysts anticipate that Humana Inc. will post 16 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Monday, September 30th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.14%. The ex-dividend date is Monday, September 30th. Humana’s dividend payout ratio (DPR) is presently 22.04%.

Analyst Ratings Changes

A number of analysts recently issued reports on HUM shares. Baird R W raised shares of Humana to a “hold” rating in a report on Thursday, May 30th. Piper Sandler assumed coverage on Humana in a research report on Wednesday, June 26th. They set an “overweight” rating and a $392.00 target price on the stock. Oppenheimer lifted their price target on Humana from $370.00 to $400.00 and gave the company an “outperform” rating in a research note on Thursday, August 1st. JPMorgan Chase & Co. increased their price target on Humana from $332.00 to $396.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 21st. Finally, TD Cowen boosted their price objective on Humana from $396.00 to $407.00 and gave the company a “buy” rating in a research report on Wednesday, July 24th. Thirteen research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Humana currently has a consensus rating of “Hold” and an average price target of $398.70.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.